Zimmer Biomet Holdings (ZBH) EBIAT (2009 - 2026)

Zimmer Biomet Holdings has reported EBIAT for 18 years, with the latest figure at $238.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT rose 30.82% year-over-year to $238.1 million; the trailing twelve-month figure through Mar 2026 stood at $761.7 million (down 16.74% YoY), and the FY2025 full-year result was $705.1 million, down 22.11% from the prior year.
• EBIAT for Q1 2026 stood at $238.1 million, up from $139.3 million in the prior quarter.
• The five-year high for EBIAT was $420.3 million in Q4 2023, with the low at -$130.5 million in Q4 2022.
• Average EBIAT over 5 years is $182.7 million, with a median of $194.0 million recorded in 2022.
• Year-over-year, EBIAT slumped 221.43% in 2022 and surged 1537.32% in 2023.
• Tracing ZBH's EBIAT over 5 years: stood at -$130.5 million in 2022, then soared by 422.07% to $420.3 million in 2023, then slumped by 42.68% to $240.9 million in 2024, then sank by 42.18% to $139.3 million in 2025, then jumped by 70.93% to $238.1 million in 2026.
• The last three EBIAT figures came in at $238.1 million (Q1 2026), $139.3 million (Q4 2025), and $230.9 million (Q3 2025), per Business Quant data.

Peer Comparison